【medical-news】雷西莫特凝胶抑制生殖器疱疹
这个帖子发布于 18 年零 143 天前，其中的信息可能已发生改变或有所发展。
Resiquimod Gel Curbs HSV-2 Genital Shedding
http://www.medscape.com/viewarticle/556264
By David Douglas
NEW YORK (Reuters Health) May 09 - Topical therapy with the investigational immune response modifier resiquimod decreases genital shedding of herpes simplex virus type 2 (HSV-2), researchers report in the May 1st issue of the Journal of Infectious Diseases.
纽约（路透社健康栏目）5月9号报道，研究人员发表在《传染病杂志》五月刊第一篇的研究表明，局部应用免疫调节剂雷西莫特能减少生殖器疱疹的Ⅱ型单纯疱疹病毒(HSV-2)排泌。
Dr. Karen E. Mark of the University of Washington, Seattle and colleagues note that the agent, an imidazoquinolinamine, stimulates production of cytokines that promote an antigen-specific T helper type 1 cell-mediated immune response. In animal models, they add, induction of such responses modifies experimental HSV infection.
西雅图华盛顿大学的Karen E. Mark博士及其同事表示， 咪唑喹啉胺类的药物刺激产生细胞因子，这些细胞因子能够促进一种特异性抗原Th1细胞介导的免疫反应。在HSV感染的动物模型实验上诱导出这样的免疫反应。
"Resiquimod works differently," from other antiviral agents, Dr. Mark told Reuters Health, "by enhancing the body's own immune system to decrease the number of future herpes outbreaks. Currently available drugs for treating genital herpes act by directly targeting the virus to shorten symptoms of a genital herpes outbreak or to prevent outbreaks while taking pills daily."
Mark博士说，雷西莫特的药理与其他抗病毒剂不同，通过增强身体自身免疫力以减少将来疱疹爆发的人数。当前治疗生殖器疱疹的有效药物通过直接针对病毒的靶向作用减少生殖器疱疹爆发的症状或预防爆发，而做到这些只需每天吃几片药。
To assess the efficacy of resiquimod 0.01% gel for reducing human anogenital HSV-2 mucosal reactivation, the researchers studied 75 subjects with genital HSV-2 who were randomized to apply the agent or the vehicle gel alone to herpes lesions twice weekly for 3 weeks.
评价0.01%雷西莫特凝胶减少人肛门生殖器HSV-2粘膜复发的功效，研究者研究了75例生殖器HSV-2感染者，随机给予雷西莫特口服或每周两次疱疹皮损处单独应用雷西莫特凝胶，连用三周。
Daily anogenital swabbing was used to evaluate shedding over the next 60 days. Recurrences during the subsequent 7 months were treated with the study gel, and during the final 60-day treatment-free period, swabs were again employed to gauge shedding.
在接下来60天用每日肛门生殖器涂搽评价排泌。使用凝胶治疗接下来的7个月中的复发，再后来的60天随意治疗期，再一次用涂搽法估计排泌。
The median lesion rates (the proportion of days with lesions) during the initial sampling period were 10% in the resiquimod group and 16% in the vehicle group. Corresponding shedding rates (the proportion of days with detectable HSV DNA) were 10% and 17%.
应用10%雷西莫特凝胶组和16%雷西莫特凝胶组在初步取样期的中位的皮损程度（皮损的日比例），其相应的排泌率（检测HSV DNA的日比例）分别是10% 和17%。
In the final sampling period, lesion rates were 3% in the resiquimod group and 22% in the vehicle group. Shedding rates were 10% and 26%.
在终末取样期，3%雷西莫特凝胶组和22%雷西莫特凝胶组的皮损程度，其排泌率分别是10% 和26%。
"This suggests," concluded Dr. Mark, that "a reduction in shedding of the herpes virus from the genital tract, and thus likely a reduction in sexual transmission of genital herpes, will be possible with the further development of drugs which work by a similar mechanism as resiquimod. More studies will be needed to confirm these findings."
Mark博士总结说，生殖道的生殖器疱疹的排泌减少，因此有可能减少生殖器疱疹的性传播，这表明要进一步研制与雷西莫特作用机制相似的药物，要做更多的研究来证实这些发现。
J Infect Dis 2007;195:1324-1331.
《传染病杂志》2007;195:1324-1331
http://www.medscape.com/viewarticle/556264
By David Douglas
NEW YORK (Reuters Health) May 09 - Topical therapy with the investigational immune response modifier resiquimod decreases genital shedding of herpes simplex virus type 2 (HSV-2), researchers report in the May 1st issue of the Journal of Infectious Diseases.
纽约（路透社健康栏目）5月9号报道，研究人员发表在《传染病杂志》五月刊第一篇的研究表明，局部应用免疫调节剂雷西莫特能减少生殖器疱疹的Ⅱ型单纯疱疹病毒(HSV-2)排泌。
Dr. Karen E. Mark of the University of Washington, Seattle and colleagues note that the agent, an imidazoquinolinamine, stimulates production of cytokines that promote an antigen-specific T helper type 1 cell-mediated immune response. In animal models, they add, induction of such responses modifies experimental HSV infection.
西雅图华盛顿大学的Karen E. Mark博士及其同事表示， 咪唑喹啉胺类的药物刺激产生细胞因子，这些细胞因子能够促进一种特异性抗原Th1细胞介导的免疫反应。在HSV感染的动物模型实验上诱导出这样的免疫反应。
"Resiquimod works differently," from other antiviral agents, Dr. Mark told Reuters Health, "by enhancing the body's own immune system to decrease the number of future herpes outbreaks. Currently available drugs for treating genital herpes act by directly targeting the virus to shorten symptoms of a genital herpes outbreak or to prevent outbreaks while taking pills daily."
Mark博士说，雷西莫特的药理与其他抗病毒剂不同，通过增强身体自身免疫力以减少将来疱疹爆发的人数。当前治疗生殖器疱疹的有效药物通过直接针对病毒的靶向作用减少生殖器疱疹爆发的症状或预防爆发，而做到这些只需每天吃几片药。
To assess the efficacy of resiquimod 0.01% gel for reducing human anogenital HSV-2 mucosal reactivation, the researchers studied 75 subjects with genital HSV-2 who were randomized to apply the agent or the vehicle gel alone to herpes lesions twice weekly for 3 weeks.
评价0.01%雷西莫特凝胶减少人肛门生殖器HSV-2粘膜复发的功效，研究者研究了75例生殖器HSV-2感染者，随机给予雷西莫特口服或每周两次疱疹皮损处单独应用雷西莫特凝胶，连用三周。
Daily anogenital swabbing was used to evaluate shedding over the next 60 days. Recurrences during the subsequent 7 months were treated with the study gel, and during the final 60-day treatment-free period, swabs were again employed to gauge shedding.
在接下来60天用每日肛门生殖器涂搽评价排泌。使用凝胶治疗接下来的7个月中的复发，再后来的60天随意治疗期，再一次用涂搽法估计排泌。
The median lesion rates (the proportion of days with lesions) during the initial sampling period were 10% in the resiquimod group and 16% in the vehicle group. Corresponding shedding rates (the proportion of days with detectable HSV DNA) were 10% and 17%.
应用10%雷西莫特凝胶组和16%雷西莫特凝胶组在初步取样期的中位的皮损程度（皮损的日比例），其相应的排泌率（检测HSV DNA的日比例）分别是10% 和17%。
In the final sampling period, lesion rates were 3% in the resiquimod group and 22% in the vehicle group. Shedding rates were 10% and 26%.
在终末取样期，3%雷西莫特凝胶组和22%雷西莫特凝胶组的皮损程度，其排泌率分别是10% 和26%。
"This suggests," concluded Dr. Mark, that "a reduction in shedding of the herpes virus from the genital tract, and thus likely a reduction in sexual transmission of genital herpes, will be possible with the further development of drugs which work by a similar mechanism as resiquimod. More studies will be needed to confirm these findings."
Mark博士总结说，生殖道的生殖器疱疹的排泌减少，因此有可能减少生殖器疱疹的性传播，这表明要进一步研制与雷西莫特作用机制相似的药物，要做更多的研究来证实这些发现。
J Infect Dis 2007;195:1324-1331.
《传染病杂志》2007;195:1324-1331
回复2 点赞
